TP53 and neoplasm: We designed this study to evaluate whether detectable tumor-specific TP53 alteration in the circulating cell-free DNA in plasma samples obtained immediately before curative-intent surgery could provide an integrative noninvasive molecular biomarker for risk level stratification.